A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects

Trial Profile

A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2016

At a glance

  • Drugs TAK 233 (Primary)
  • Indications Stress incontinence
  • Focus Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 27 Oct 2014 Last checked against ClinicalTrials.gov.
    • 20 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top